{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:08:36Z","timestamp":1784153316356,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["trasci.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.transci.2024.104002","type":"journal-article","created":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T14:21:38Z","timestamp":1725805298000},"page":"104002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Relationship between mutations in severe hemophilia A and risk of inhibitor development: A large single-center study"],"prefix":"10.1016","volume":"63","author":[{"given":"Arash Ahmadfard","family":"Moghadam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Reza","family":"Manafzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MR","family":"Nikoonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Somayeh","family":"Moazezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadijeh Dajliry","family":"Nekoei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farahnaz","family":"Ramezan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davood","family":"Bashash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Hamidpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadi","family":"Tabibian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.transci.2024.104002_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/hematolrep15010014","article-title":"Haemophilia A: a review of clinical manifestations, treatment, mutations, and the development of inhibitors","volume":"15","author":"Sarmiento Doncel","year":"2023","journal-title":"Hematol Rep"},{"issue":"2","key":"10.1016\/j.transci.2024.104002_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejmhg.2010.10.005","article-title":"Molecular genetics of hemophilia A: clinical perspectives","volume":"11","author":"Tantawy","year":"2010","journal-title":"Egypt J Med Hum Genet"},{"issue":"2","key":"10.1016\/j.transci.2024.104002_bib3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/hae.13081","article-title":"Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System","volume":"23","author":"Kulkarni","year":"2017","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.transci.2024.104002_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00002281-199801000-00013","article-title":"Rheumatic manifestations of hematologic disorders","volume":"10","author":"Avi\u00f1a-Zubieta","year":"1998","journal-title":"Curr Opin Rheuma"},{"issue":"226","key":"10.1016\/j.transci.2024.104002_bib5","first-page":"181","article-title":"Haemophilic arthritis","volume":"58","author":"Steven","year":"1986","journal-title":"Q J Med"},{"issue":"6","key":"10.1016\/j.transci.2024.104002_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103212","article-title":"Tailored prophylaxis in children with severe hemophilia: a four-year Iranian study","volume":"60","author":"Baghaipour","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2024.104002_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.thromres.2018.05.027","article-title":"Risk factors for inhibitor development in severe hemophilia a","volume":"168","author":"Garagiola","year":"2018","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.transci.2024.104002_bib8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1134\/S1022795421080111","article-title":"Genetic risk factors for inhibitor development in hemophilia A","volume":"57","author":"Pshenichnikova","year":"2021","journal-title":"Russ J Genet"},{"issue":"Suppl 2","key":"10.1016\/j.transci.2024.104002_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1351-8216.2001.00134.x","article-title":"Inhibitor development in correlation to factor VIII genotypes","volume":"8","author":"Oldenburg","year":"2002","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.transci.2024.104002_bib10","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1538-7836.2012.04691.x","article-title":"Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A: FVIII products and inhibitors in hemophilia A","volume":"10","author":"Mancuso","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"02","key":"10.1016\/j.transci.2024.104002_bib11","first-page":"247","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability","volume":"74","author":"Verbruggen","year":"1995","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.transci.2024.104002_bib12","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/j.1538-7836.2008.02926.x","article-title":"Developing a new generation of tests for genotyping hemophilia-causative rearrangements involving int22h and int1h hotspots in the factor VIII gene: <I>Genotyping int22h- and int1h-mediated rearrangements<\/i>.","volume":"6","author":"Rossetti","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.transci.2024.104002_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/hae.13143","article-title":"Multiplex ligation\u2010dependent probe amplification as first mutation screening for large deletions and duplications in haemophilia","volume":"23","author":"Belvini","year":"2017","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.transci.2024.104002_bib14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/humu.10212","article-title":"Human gene mutation database (HGMD\u00ae): 2003 update: Hgmd 2003 update","volume":"21","author":"Stenson","year":"2003","journal-title":"Hum Mutat"},{"issue":"4","key":"10.1016\/j.transci.2024.104002_bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nmeth.2890","article-title":"MutationTaster2: mutation prediction for the deep-sequencing age","volume":"11","author":"Schwarz","year":"2014","journal-title":"Nat Methods"},{"issue":"5","key":"10.1016\/j.transci.2024.104002_bib16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"10","key":"10.1016\/j.transci.2024.104002_bib17","article-title":"Large intron inversions in Romanian patients with hemophilia A-first report","volume":"59","author":"Brinza","year":"2023","journal-title":"Med (Kaunas)"},{"key":"10.1016\/j.transci.2024.104002_bib18","doi-asserted-by":"crossref","DOI":"10.1046\/j.1538-7836.2003.t01-4-00326.x","article-title":"Significant prevalence of the intron 1 factor VIII gene inversion among patients with severe haemophilia A in the Czech Republic","volume":"1","author":"Habart","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.transci.2024.104002_bib19","first-page":"352","article-title":"Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A","volume":"53","author":"Sawecka","year":"2005","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"2","key":"10.1016\/j.transci.2024.104002_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MBC.0000000000000212","article-title":"Carrier and prenatal diagnostic strategy and newly identified mutations in Hungarian haemophilia A and B families","volume":"26","author":"Bors","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"10.1016\/j.transci.2024.104002_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2516.2005.01069.x","article-title":"Mutation analysis in 51 patients with haemophilia A: report of 10 novel mutations and correlations between genotype and clinical phenotype","volume":"11","author":"Hill","year":"2005","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.transci.2024.104002_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13052-020-00878-5","article-title":"Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?","volume":"46","author":"Sherief","year":"2020","journal-title":"Ital J Pedia"},{"issue":"8","key":"10.1016\/j.transci.2024.104002_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/2040620718785363","article-title":"Clinicopathological parameters influencing inhibitor development in patients with hemophilia A receiving on-demand therapy","volume":"9","author":"Arshad","year":"2018","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"10.1016\/j.transci.2024.104002_bib24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review: EPIDEMIOLOGY OF INHIBITORS IN HAEMOPHILIA","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.transci.2024.104002_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/hae.12566","article-title":"Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A","volume":"21","author":"Hashemi","year":"2015","journal-title":"Haemophilia"},{"issue":"12","key":"10.1016\/j.transci.2024.104002_bib26","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1111\/j.1538-7836.2008.03187.x","article-title":"Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice","volume":"6","author":"ter Avest","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.transci.2024.104002_bib27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2516.2010.02422.x","article-title":"Treatment related factors and inhibitor development in children with severe haemophilia A: INHIBITOR RISK FACTORS IN HAEMOPHILIA A","volume":"17","author":"Maclean","year":"2011","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.transci.2024.104002_bib28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1538-7836.2007.02595.x","article-title":"Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A","volume":"5","author":"Gouw","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.transci.2024.104002_bib29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2141.2005.05605.x","article-title":"Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study","volume":"130","author":"Santagostino","year":"2005","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.transci.2024.104002_bib30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2516.2010.02231.x","article-title":"Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report: NON-GENETIC RISK FACTORS FOR INHIBITOR FORMATION","volume":"16","author":"Astermark","year":"2010","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.transci.2024.104002_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/hae.13075","article-title":"Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models","volume":"22","author":"L\u00f6vgren","year":"2016","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.transci.2024.104002_bib32","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1055\/s-0038-1649954","article-title":"Haemophilia A: mutation type determines risk of inhibitor formation","volume":"74","author":"Schwaab","year":"1995","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.transci.2024.104002_bib33","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.transci.2024.104002_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2013-12-530113","article-title":"The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics","volume":"125","author":"Sauna","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transci.2024.104002_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12723","article-title":"F8 gene mutation spectrum in severe hemophilia A with inhibitors: a large cohort data analysis from a single center in China","volume":"6","author":"Sun","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"21","key":"10.1016\/j.transci.2024.104002_bib36","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.transci.2024.104002_bib37","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","article-title":"Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review: I Inhibitor rate after plasma-derived or recombinant FVIII concentrates\/i","volume":"8","author":"Iorio","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.transci.2024.104002_bib38","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1055\/s-0033-1356715","article-title":"Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update","volume":"39","author":"Franchini","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2024.104002_bib39","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1160\/TH14-07-0621","article-title":"Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A: a patient-level meta-analysis","volume":"113","author":"Marcucci","year":"2015","journal-title":"Thromb Haemost"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050224001733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050224001733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T02:51:35Z","timestamp":1732675895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050224001733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1473050224001733"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2024.104002","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between mutations in severe hemophilia A and risk of inhibitor development: A large single-center study","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2024.104002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104002"}}